Search
22 stories for“drug development”
Rentosertib was built to treat pulmonary fibrosis. In 42 patients, blood proteins read by six independent clocks came out three to four years younger after a month. Independent doctors say a younger score is not a younger person.
Sep 15, 2026
SGLT2 inhibitors were developed to lower blood sugar by making you urinate it out. The glucose effect turned out to be the least interesting thing about them, and the kidney trials changed how this complication is treated.
Jul 25, 2026
New guidance targets a threat the agency calls one of the most neglected in global health. The problem is not just the infections, it is how few drugs exist to treat them.
Aug 4, 2026
Semaglutide and tirzepatide went from diabetes treatment to celebrity shortcut to a genuine health story. What happens when one drug becomes a cultural moment.
Apr 20, 2024
GLP-1 receptor agonists did not start as weight loss drugs. Here is the biology behind Ozempic, Mounjaro and the hormone they mimic.
Jan 25, 2024
Nausea is the least of it. Here is an honest look at GLP-1 side effects, the thyroid warning, pancreatitis and who is advised to avoid them.
Jul 10, 2024
Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026
Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026
Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024
Insulin is a peptide. So is Ozempic. So is the unlabelled vial someone is selling on Telegram. The word describes a chemical class, not a level of evidence, and that gap is where the market lives.
Aug 11, 2026
Type 1 and type 2 are the two everyone knows. LADA is regularly mistaken for type 2 in adults, and MODY is a single-gene condition that can sometimes be treated with a tablet instead of insulin. The label decides the therapy.
Jul 7, 2026
The IDF and Diabetes and Ramadan International Alliance stratify patients into low, moderate and high risk, and updated the calculator for 2026. The assessment is meant to happen six to eight weeks ahead, which is when almost nobody books it.
Aug 3, 2026
Two individualized antisense treatments reduced the effects of a rare SCN2A disorder. The results are hopeful, but they come from two carefully monitored patients, not a broad trial.
Aug 1, 2026
The label is contested, the thresholds differ between guidelines, and most people who have it never progress. It is also the one point in this whole condition where a trial showed you can change the outcome by more than half.
Jul 10, 2026
Diabetes care is organised around bringing numbers down, which makes it easy to forget that the acute danger points the other way. The ADA defines three levels of hypoglycaemia, and the third one requires another person.
Aug 6, 2026
IDF figures put UAE adult prevalence at 20.7 per cent and Saudi Arabia at 23.1 per cent, against a global figure around a tenth. The explanation is not one thing, and one of the contributing factors is barely three generations old.
Jul 16, 2026
A tiny implant paired with camera glasses can return useful central vision to some people with advanced macular degeneration, and Europe has cleared its sale.
Jul 23, 2026
